Skip to main content
Clinical Trials/NCT06385587
NCT06385587
Completed
N/A

Technology-based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients Initiating Chemoradiation: A Pilot Study

Aptar Digital Health1 site in 1 country33 target enrollmentJune 6, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
Aptar Digital Health
Enrollment
33
Locations
1
Primary Endpoint
Users' satisfaction
Status
Completed
Last Updated
6 months ago

Overview

Brief Summary

The goal of this observational study is to assess the satisfaction and usability of an interactive and patient-centered mobile application (app), Oleena™, designed to assist head and neck cancer patients undergoing chemoradiation in managing common and distressing symptoms in real-time, as well as to assess the satisfaction and usability of the related HCP web portal. Additional secondary usage and clinical endpoints that would be used to assess intervention efficacy in future trials will be collected.

Registry
clinicaltrials.gov
Start Date
June 6, 2024
End Date
September 25, 2025
Last Updated
6 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Aptar Digital Health
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≥18 years old
  • Planned to initiate chemoradiation for locally advanced head and neck cancer at Moffitt Cancer Center
  • ECOG performance status ≤2
  • Able to speak and read US English or Spanish
  • Able to provide informed consent
  • Owns a smartphone with an iOS or Android operating systemcompatible with Oleena
  • Able to access the internet
  • Willing to use a mobile app for symptom management

Exclusion Criteria

  • Documented or observable psychiatric or neurological disorders that would interfere with study participation (e.g., psychosis, active substance abuse).
  • A prior cancer diagnosis except for non-melanoma skin cancer.
  • Currently enrolled in an industry-sponsored clinical trial.
  • Pregnant women.
  • Patients undergoing RE-irradiation
  • Patients who meet the inclusion criteria may be excluded at Investigator's discretion

Outcomes

Primary Outcomes

Users' satisfaction

Time Frame: End of study - Day 90 +/-10 from first radiotherapy

Users' (participants and HCPs) level of satisfaction with the symptom management app, which will be assessed via a validated, 4-item scale, Acceptability of Intervention Measures (score range 0-20)

Secondary Outcomes

  • Feasibility of the technology enabled symptom management solution(Assessed up to 90 days)
  • Usability of the technology enabled symptom management solution(Day 30 and Day 90 +/-10 from first radiotherapy)
  • Appropriateness of the recommendations(After 15 and then 30 patients have reached Day 30 and then Day 90)
  • Semi-structured exit interviews(End of study - Day 90 +/-10 from first radiotherapy)

Study Sites (1)

Loading locations...

Similar Trials